HealthcareServices

Renal Biomarkers Market Growth Projection: Expected to Surpass $2.04 Billion by 2030 at 8.2% CAGR

March 2, 2026March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the renal biomarkers market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Renal Biomarkers Market size between 2026 and 2035?

The renal biomarkers market has witnessed substantial expansion in recent years. It is anticipated to expand from $1.37 billion in 2025 to $1.49 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.6%. The historical growth trajectory is primarily driven by the escalating prevalence of chronic kidney disease, increased utilization of creatinine and urea testing, the broadening of diagnostic laboratory infrastructure, rising awareness concerning the early detection of kidney injury, and enhancements in immunoassay technologies.

The renal biomarkers market is projected to experience substantial expansion in the coming years, with its valuation expected to reach $2.04 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast period is primarily driven by factors such as the greater adoption of precision medicine approaches, a surge in demand for predictive diagnostics in renal conditions, the broadening scope of biomarker-based clinical research, the increasing incorporation of AI into biomarker analysis, and an intensified focus on individualized nephrology care. Key trends anticipated over this forecast horizon include the wider acceptance of new kidney injury biomarkers, an uptick in the utilization of multi-biomarker panels for diagnostic purposes, a heightened need for the early identification of kidney damage, the expansion of non-invasive urine-based testing methods, and a sharpened emphasis on monitoring disease progression.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7711&type=smp

Which Drivers Are Impacting Market Performance In The Renal Biomarkers Market?

The escalating prevalence of chronic kidney disease (CKD) is anticipated to drive expansion within the renal biomarkers market in the future. This chronic condition involves a progressive decrease in kidney function, impairing the body’s capacity to filter waste, sustain fluid balance, and manage vital electrolytes. The growing occurrence of CKD primarily stems from an aging demographic, diabetes, high blood pressure, and genetic predispositions, factors that collectively lead to increased instances of kidney complications and fatalities. In clinical settings, renal biomarkers are vital for facilitating earlier detection, tracking the advancement of the disease, and supporting prompt treatment to avert kidney failure. For example, data from December 2024, released by the Australian Institute of Health and Welfare, an Australia-based government entity, indicated that chronic kidney disease represented 1.1% of Australia’s total disease burden, with age-adjusted figures revealing that males faced 1.3 times the burden compared to females. Consequently, the increasing load of chronic kidney disease is propelling the expansion of the renal biomarkers market.

What Segment Types Are Examined In The Renal Biomarkers Market?

The renal biomarkers market covered in this report is segmented –

1) By Biomarker Type: Functional Biomarker, Up Regulated Protein, Other Biomarker Types

2) By Diagnostic Technique: Enzyme-Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LS-MS)

3) By Application: Diagnosis And Disease Progression Monitoring, Clinical Research

4) By End User: Hospitals, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Functional Biomarker: Creatinine, Urea, Cystatin C, Bicarbonate

2) By Up Regulated Protein: Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), Interleukin-18 (IL-18)

3) By Other Biomarker Types: Proximal Tubule Injury Biomarkers, Acute Kidney Injury Biomarkers, Chronic Kidney Disease Biomarkers

Which Trends Are Guiding The Evolution Of The Renal Biomarkers Market?

Leading companies within the renal biomarkers market are progressively engaging in sophisticated collaborations with research entities and AI-powered biotechnology firms. These efforts aim to advance biomarker discovery, refine patient stratification, and enhance precision diagnostic capabilities. The goal of these strategic alliances is to expedite the identification and validation of new biomarkers, which support early disease detection, more accurate risk assessment, and personalized treatment approaches for kidney disorders. For example, in November 2024, MultiOmic Health, a UK-based AI-powered drug discovery company, pinpointed novel patient endotypes and proprietary biomarkers for diabetic kidney disease (DKD) through a research collaboration with the Northern Care Alliance NHS Foundation Trust. These biomarkers facilitate precise patient segmentation and foster the development of targeted diagnostic tools and therapeutics, thereby supporting improved clinical decision-making and outcomes in kidney care.

Who Are The Major Companies Operating In The Renal Biomarkers Market?

Major companies operating in the renal biomarkers market are Abbott Laboratories, BioPorto Diagnostics A S, Roche Holding AG, Thermo Fisher Scientific, bioMérieux SA, Randox Laboratories, Siemens Healthineers, Beckman Coulter Inc., Astute Medical Inc., Sphingotec GmbH, Bio Rad Laboratories India Pvt. Ltd., Enzo Biochem Inc., PerkinElmer Inc., Alere Inc., Bio Techne Corp., DiaSorin S.p.A., EKF Diagnostics Holdings plc, Fujirebio Diagnostics Inc., Gold Standard Diagnostics Corp., Merck KGaA, Myriad RBM Inc., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, R And D Systems Inc., Roche Diagnostics International Ltd, Sekisui Chemical Co. Ltd., Sysmex Corporation, Tosoh Bioscience Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Renal Biomarkers Market?

North America was the largest region in the renal biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The regions covered in the renal biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Renal Biomarkers Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7711&type=smp

Browse Through More Reports Similar to the Global Renal Biomarkers Market 2026, By The Business Research Company

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Kidney Cancer Diagnostics And Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-cancer-diagnostics-and-therapeutics-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795